Structure–activity relationship of tacrine and its analogues in relation to inhibitory activity against Alzheimer’s disease

Structural, harmonic force field and vibrational studies of cholinesterase inhibitor tacrine used for treatment of Alzheimer's disease

“…From 1950, tacrine was used experimentally to treat reverse cholinergic coma in animals and, since 1993 its use was approved by the US Food and Drug Administration to treat Alzheimer's disease [ 1 , 2 ]. Thus, the interest in studying it has considerably increased, as it is evidenced by multiple studies carried out from different points of view [ [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] ]. Sorrenti et al have established the presence of a unique anhydrous crystalline phase of tacrine hydrochloride using the recrystallization of hot saturated solutions of two mono and di-hydrate forms obtained from different solvents [ 17 ].…”